Biomerica Reports Positive IBS Therapy Data and Confirms Medicare Reimbursement Rate
Key Facts
- •Real-world data showed 59.4% of IBS patients achieved a 30% or greater reduction in abdominal pain using inFoods therapy.
- •68.1% of patients achieved a 30% or greater reduction in bloating, consistent with FDA-recognized endpoints.
- •A national Medicare payment rate of $300 has been established, effective January 1, 2026.
Biomerica (BMRA) has announced positive real-world clinical data for its inFoods IBS therapy, marking a significant milestone for the company's clinical validation. The data revealed that 59.4% of patients experienced a reduction of 30% or more in abdominal pain, demonstrating strong efficacy. Additionally, 68.1% of participants reported a similar improvement in bloating, meeting key endpoints recognized by the FDA. Parallel to these clinical results, the Centers for Medicare & Medicaid Services (CMS) established a national payment rate of $300 for the therapy. This reimbursement rate is scheduled to take effect on January 1, 2026, providing a clear path for commercial scaling and revenue generation. Analysts view these developments as a major boost for the biotech firm's market confidence and future growth prospects.
freemium.freemium.cta.signup
freemium.freemium.cta.signup_button